AU
UK
CA
NZ
IND
US
Last update at 2026-06-23T20:27:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday?
Fri 21 Mar 25, 11:06 AMAkebia Therapeutics Announces Pricing of Public Offering of Common Stock
Thu 20 Mar 25, 02:17 AMAkebia Therapeutics Announces Proposed Public Offering of Common Stock
Wed 19 Mar 25, 08:01 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -3.72100M | -69.41000M | -51.92500M | -92.56200M | -282.84000M |
| Minority interest | - | - | - | - | - |
| Net income | -5.34500M | -69.41000M | -51.92500M | -106.00900M | -244.87000M |
| Selling general administrative | 107.48M | 101.94M | 3.24M | 141.87M | 177.65M |
| Selling and marketing expenses | - | 4.60M | 100.23M | -3.17500M | 174.16M |
| Gross profit | 196.73M | 97.00M | 120.47M | 207.81M | 60.18M |
| Reconciled depreciation | 1.27M | 37.50M | 37.64M | 37.70M | 37.97M |
| Ebit | 20.46M | -51.22500M | -45.89300M | -63.18200M | -303.28800M |
| Ebitda | 21.73M | -13.72100M | -8.26600M | -46.34300M | -265.31800M |
| Depreciation and amortization | 1.27M | 37.50M | 37.63M | 16.84M | 37.97M |
| Non operating income net other | - | - | - | 2.24M | 2.41M |
| Operating income | 23.50M | -50.47200M | -46.25600M | -63.18200M | -265.31800M |
| Other operating expenses | 212.70M | 210.65M | 240.88M | 355.78M | 478.90M |
| Interest expense | 24.18M | 18.18M | 6.03M | 15.69M | -19.93600M |
| Tax provision | 1.62M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Interest income | - | - | - | - | - |
| Net interest income | -24.17900M | -18.18500M | -6.25000M | -15.68700M | -19.93600M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | 15.93M | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1.62M | - | 41.68M | 13.45M | -37.97000M |
| Total revenue | 236.20M | 160.18M | 194.62M | 292.60M | 213.58M |
| Total operating expenses | 173.24M | 147.47M | 166.73M | 270.99M | 325.50M |
| Cost of revenue | 39.46M | 63.18M | 74.15M | 84.80M | 153.39M |
| Total other income expense net | -27.22000M | -18.93800M | -5.66900M | -29.38000M | -17.52200M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -5.34500M | -69.41000M | -56.94600M | -92.56200M | -282.84000M |
| Net income applicable to common shares | - | - | - | -92.56200M | -282.84000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 376.56M | 220.67M | 241.70M | 351.83M | 525.55M |
| Intangible assets | - | - | 36.04M | 72.08M | 108.13M |
| Earning assets | - | - | - | - | - |
| Other current assets | -62.64100M | 11.35M | 20.24M | 33.54M | 33.14M |
| Total liab | 343.95M | 269.86M | 272.29M | 342.49M | 449.09M |
| Total stockholder equity | 32.61M | -49.18500M | -30.58400M | 9.34M | 76.46M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 101.67M | 56.02M | 38.26M | 66.25M | 99.65M |
| Common stock | 0.00200M | 0.00200M | 0.00200M | 0.00200M | 0.00100M |
| Capital stock | 0.00200M | 0.00200M | 0.00200M | 0.00200M | 0.00100M |
| Retained earnings | -1683.70500M | -1678.36000M | -1608.95000M | -1552.91300M | -1460.35100M |
| Other liab | - | - | - | 158.25M | 158.90M |
| Good will | 59.04M | 59.04M | 59.04M | 55.05M | 55.05M |
| Other assets | - | - | - | 94.48M | 640.27M |
| Cash | 184.84M | 51.87M | 42.92M | 90.47M | 149.80M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 162.94M | 80.91M | 99.87M | 124.76M | 256.49M |
| Current deferred revenue | - | 15.73M | 22.94M | 3.74M | 20.91M |
| Net debt | 31.45M | 136.86M | 61.26M | 9.32M | -13.75200M |
| Short term debt | 40.08M | 9.71M | 24.04M | 36.74M | 102.34M |
| Short long term debt | - | - | 17.50M | 32.00M | 97.54M |
| Short long term debt total | 216.30M | 188.73M | 104.18M | 99.78M | 136.05M |
| Other stockholder equity | 1716.31M | 1629.17M | 1578.36M | 1562.25M | 1536.80M |
| Property plant equipment | - | - | - | 5.21M | 6.75M |
| Total current assets | 184.84M | 113.83M | 118.15M | 184.95M | 272.01M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | -117.79500M | -86.72400M |
| Short term investments | - | - | - | - | 0.00000M |
| Net receivables | 47.03M | 34.37M | 39.29M | 39.18M | 50.88M |
| Long term debt | 48.25M | 38.69M | 17.18M | 34.08M | 1.82M |
| Inventory | 15.61M | 16.24M | 15.69M | 21.76M | 38.20M |
| Accounts payable | 21.18M | 15.18M | 14.63M | 18.02M | 33.59M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.00600M | 0.00600M | 0.00600M | 0.00600M | 0.00600M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.00200M | 0.00100M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -1552.91300M | -1460.35100M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 132.68M | 37.38M | 10.77M | 5.37M | 49.75M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 191.72M | 106.84M | 123.55M | 166.88M | 253.54M |
| Capital lease obligations | 3.55M | 8.95M | 13.44M | 33.70M | 38.51M |
| Long term debt total | - | - | - | - | 1.82M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.03300M | 0.00000M | -0.11400M | 40.00M |
| Change to liabilities | - | - | - | -34.64600M | -48.89600M |
| Total cashflows from investing activities | -7.92600M | -0.03300M | - | -0.11400M | 39.94M |
| Net borrowings | 9.54M | 7.90M | -32.00000M | -33.00000M | -33.00000M |
| Total cash from financing activities | 72.93M | 49.66M | -25.20600M | 14.60M | 133.73M |
| Change to operating activities | - | - | - | -37.98200M | -48.63500M |
| Net income | -5.34500M | -69.41000M | -51.92500M | -92.56200M | -282.84000M |
| Change in cash | 132.99M | 8.97M | -48.59000M | -58.67000M | -79.29300M |
| Begin period cash flow | 53.55M | 44.58M | 93.17M | 151.84M | 231.13M |
| End period cash flow | 186.54M | 53.55M | 44.58M | 93.17M | 151.84M |
| Total cash from operating activities | 67.99M | -40.65900M | -23.38400M | -73.15400M | -252.96500M |
| Issuance of capital stock | 66.68M | 42.65M | -0.00100M | 7.12M | 88.20M |
| Depreciation | 1.27M | 37.50M | 41.85M | 37.70M | 37.97M |
| Other cashflows from investing activities | -7.92600M | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -23.12500M | -28.40100M | -2.54200M | 19.79M | -25.84700M |
| Change to account receivables | -14.14200M | 4.05M | 0.99M | 11.70M | -24.02200M |
| Sale purchase of stock | - | -1.27200M | 0.00000M | 7.60M | 88.95M |
| Other cashflows from financing activities | -0.06300M | 0.39M | 0.00100M | 40.48M | 45.53M |
| Change to netincome | - | - | - | 46.73M | 37.08M |
| Capital expenditures | 0.29M | 0.03M | 0.00000M | 0.11M | 0.06M |
| Change receivables | - | - | - | 11.70M | -24.02200M |
| Cash flows other operating | - | - | - | -61.86600M | 53.61M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | -58.67000M | -79.29300M |
| Change in working capital | 16.47M | -39.67600M | -20.72700M | -1.43500M | -108.41800M |
| Stock based compensation | 11.28M | 7.78M | 9.32M | 17.85M | 22.73M |
| Other non cash items | 44.31M | 23.15M | -1.89500M | -34.70300M | 41.01M |
| Free cash flow | 67.99M | -40.69200M | -23.38400M | -73.26800M | -253.02400M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AKBA Akebia Ther |
0.01 0.92% | 1.10 | - | 35.71 | 1.60 | 11.75 | 1.06 | 11.51 |
| ZTS Zoetis Inc |
0.95 1.25% | 76.84 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
0.42 1.37% | 30.98 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% | 149.28 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| GALDY GALDERMA GROUP AG |
0.48 1.12% | 43.42 | 74.21 | 41.67 | 8.64 | 5.55 | 9.15 | 42.22 |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
245 First Street, Cambridge, MA, United States, 02142
| Name | Title | Year Born |
|---|---|---|
| Mr. John P. Butler MBA | CEO, Pres & Director | 1964 |
| Mr. David A. Spellman | Sr. VP, CFO & Treasurer | 1977 |
| Mr. Michel Dahan | Sr. VP & COO | 1979 |
| Dr. Steven Keith Burke | Sr. VP of R&D and Chief Medical Officer | 1961 |
| Ms. Violetta Cotreau | Sr. VP, Chief Accounting Officer & Principal Accounting Officer | 1973 |
| Ms. Nicole R. Hadas | Sr. VP, Chief Legal Officer & Sec. | 1973 |
| Mercedes Carrasco | Director of Corp. Communications | NA |
| Mr. Douglas Jermasek M.B.A. | VP of Marketing & Strategy | NA |
| Ms. Meredith Bowman | Sr. VP of People | NA |
| Dr. Thierry Bilbault Ph.D. | Sr. VP of Manufacturing & Pharmaceutical Devel. | 1959 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...